and decreases in tumor size and catecholamine levels in plasma and urine. He had been in a clinically stable condition for 18 months but died 34 months after starting of this treatment because the CVD regimen became ineffective and rapid growth of the metastatic tumors occurred.
The other patient, a 35-year-old man showed no significant change in tumor size but decreases in hormonal levels in response to CVD regimen.
The patient has been in clinically stable condition in a follow-up of 24 months. The combined chemotherapy with CVD appears to be effective for advanced malignant pheochromocytoma. Blood pressure was mildly elevated and plasma catecholamine levels were noticeably elevated. He was suspected of having recurrent pheochromocytoma and then referred to our hospital.
The plasma NE level on admission was high at 11000 pg/ml (normal, up to 250 pg/ml).
CT scans showed an adenopathy in the paraaortic region (Fig. 2) . A sectional rentogenography of the sternum showed an osteolytic region.
He was given a course of irradiation (60 Gy over 6 weeks) to the osteolytic area of the sternum, and the osteolytic area became smaller and his tenderness at the sternum disappeared.
His blood pressure and heart rate were under better control with doxazosin, 6 mg/day, and a-methyl-p-tyrosine, a catecholamine synthesis inhibitor, 1000 mg/day, but urinary NE and vanillylmandelic acid levels remained noticeably high.
In January, 1991 the patient began treatment with CT scans of abdomen in case 1 (top) before chemotherapy (7/90) and (bottom) after eight cycles (8/91). Note disappearance of a paraaortic adenopathy (arrow in top).
CVD regimen which consisted of intravenous administration of cyclophosphamide, 750 mg/m2 on day 1, vincristine or vindesine, 1.4 mg/m2 on day 1, and dacarbazine 600 mg/m2 on days 1 and 2, in 21-to 28-day cycles [14] . By the end of the third cycle of the chemotherapy, he became asymptomatic and there was significant regression of the paraaortic tumors and reduction of urinary catecholamines.
After 4 cycles of the CVD regimen he was discharged from the hospital but continued to receive this treatment at the outpatient clinic every 3 to 4 weeks. After 8 cycles of the chemotherapy, radiological studies showed no evidence of the disease within the abdomen (Fig. 2) , but plasma NE (730 pg/ml) did not fall to the normal range. He had myelosuppression with a slight reduction in erythrocyte and leukocyte counts as a side effect of this treatment, but this was tolerable and reversible.
The patient remained asymptomatic until the 16th cycle of the chemotherapy in May, 1992, when plasma NE was high (2000 pg/ml). Two months later, a CT scan of the abdomen showed recurrent retroperitoneal tumors. The tumors were progressing rapidly in spite of the CVD regimen. The combination therapy was discontinued because he had an episode of severe interstitial pneumonitis, probably due to the side effect of the chemotherapy and/or radiation, that responded to high doses of methylprednisolone.
Although he did not have any severe signs and symptoms due to the catecholamine excess, his condition continued to worsen because of the rapid growth of the tumors and he died in October, 1993. scan showed multiple masses in the lungs (Fig. 3) , he remained asymptomatic and the plasma NE level was up only slightly (350 pg/ml) and plasma epinephrine was 71 pg/ml (normal, up to 100 pg/ ml). In February, 1993 a lung biopsy specimen showed metastatic pheochromocytoma. Informed consent was obtained from the patient, and the decision was then made to give him our proposed CVD regimen for 5 cycles. After the third cycle of the chemotherapy, plasma NE returned to normal (160-180 pg/ml, Fig. 4 ). There was slight regression in the size (about 10%) of pulmonary nodules on CT scan. The patient had mild reversible erythrocytopenia and granulocytopenia, which was controlled without any medication. He has not been treated with the CVD regimen since August, 1993, but metastatic pheochromocytomas in the lung have not increased in size and plasma catecholamine levels remain normal, and he continues to feel well and leads a full and active life.
Discussion
Malignant pheochromocytoma is an uncommon tumor which accounts for 10-20% of all cases of pheochromocytoma [1] [2] [3] [4] 15] . The diagnosis of a malignant pheochromocytoma cannot be accurately determined by histologic findings and is instead depend on distant metastasis which occurs at a site where chromaffin tissue is not otherwise found, such as lymph nodes, liver, bones, or lungs [16] . NOSHIRO et al.
Various conventional chemotherapy regimens have been used and had little effect [9, 15, 17] , and the mean 5-year survival rate is only about 40% [15] .
Recently, however, Averbuch et al. [11] reported that a combination chemotherapy with CVD in 14 patients with malignant pheochromocytoma induced a tumor response in 57% and a hormonal response in 79%. This CVD regimen was also effective in our two cases. According to the criteria of patient's responses to therapy by Averbuch et al. [11] , our case 1 showed a complete tumor response and a partial hormonal response although these effects were temporary, and our case 2 showed a slight but apparent hormonal response but no change in tumor response as they defined less than a 25% decrease in tumor size as "no change".
Sato et al. [18] have reported that the CVD regimen was effective in 11 (78.6%) out of 14 malignant pheochromocytoma, including our case 1. Because malignant pheochromocytoma is a rare tumor, survival data relating to patients with malignant pheochromocytoma have not been reported since the CVD regimen was applied to this disease [19] [20] [21] .
As malignant pheochromocytoma often grows relatively slow [22] , one might speculate that the prognoses of the present two cases could have been the same as they were or even better if they had not been treated with CVD therapy. We cannot confirm this sort of speculation.
Further controlled study is necessary to answer this question. Adverse effects of the CVD therapy have been reported to be mild and well tolerated [11] . Reversible myelosuppression, and neurologic and gastrointestinal side effects are commonly seen. In our two cases, reversible granulocytopenia and erythrocytopenia were seen without significant sequential complications. Since our case 1 had severe interstitial pneumonitis which responded promptly to therapy with methyl prednisolone, the CVD regimen had to be discontinued.
The cause of the interstitial pneumonitis in our case 1 was thought to the side effects of the CVD regimen and/or radiation.
1311-MIBG therapy [6 , 7] is another newly developed treatment for malignant pheochromocytoma. Krempf et al. [7] reported that treatment with 1311 MIBG was effective in 9 out of 15 patients with malignant pheochromocytoma.
These results are close to those observed with CVD therapy reported by Averbuch [11] . This 1311-MIBG therapy is necessary for radiotherapeutic facilities, whereas CVD therapy can be used in any hospital. Since response to therapy, whether with chemotherapy or 1311-MIBG, is variable, it is difficult to determine the factor(s) or clinical features which can anticipate the effectiveness of chemotherapy or 131I-MIBG radiotherapy.
Comparative studies or associated treatments need to be investigated.
Plasma catecholamine concentrations were high 
